Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Department of Pediatrics, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Eur J Clin Nutr. 2022 Jun;76(6):848-854. doi: 10.1038/s41430-021-01050-w. Epub 2021 Nov 29.
Vascular calcification is one of the most prevalent disorders in pediatric hemodialysis patients that eventually lead to cardiovascular morbidity. Vitamin K2 was investigated in adults in previous studies and showed favorable effects on calcification markers. Our aim in this study was to evaluate the efficacy and safety of vitamin K2 and cholecalciferol on the calcification regulators in pediatric patients.
A prospective, randomized and controlled trial was conducted on sixty hemodialysis pediatric patients who were divided to four groups; Group 1: administered 100 µg of vitamin K2 (MK-7); Group 2: administered 10 µg of native vitamin D; Group 3: administered 100 µg of vitamin K2 (MK-7) in addition 10 µg of native vitamin D, and Group 4: administered the standard therapy only. The duration of supplementation was 4 months. In addition to a group of healthy normal control of age and sex-matched.
At the end of the study period, serum levels of FGF23, dp-uc-MGP, and uc-OC were measured. It was found that serum levels of dp-uc-MGP, uc-OC, and FGF23 were significantly higher (p < 0.05) in the hemodialysis patients as compared to the healthy normal control. After 4 months, group 3 revealed the most significant decrease in dp-uc-MGP, uc-OC as compared to the other groups. However, there was no change in FGF23.
Vitamin K2 and native vitamin D showed a beneficial effect on calcification regulators in pediatric hemodialysis patients.
clinical trial.gov (NCT04145492).
血管钙化是儿科血液透析患者中最常见的疾病之一，最终导致心血管发病率。先前的研究已经在成年人中研究了维生素 K2，并显示其对钙化标志物有有利影响。我们在这项研究中的目的是评估维生素 K2 和胆钙化醇对儿科患者钙化调节剂的疗效和安全性。
对 60 名接受血液透析的儿科患者进行了前瞻性、随机对照试验，将患者分为四组；第 1 组：给予 100µg 维生素 K2（MK-7）；第 2 组：给予 10µg 天然维生素 D；第 3 组：给予 100µg 维生素 K2（MK-7），外加 10µg 天然维生素 D，第 4 组：仅给予标准治疗。补充剂的持续时间为 4 个月。除了一组年龄和性别匹配的健康正常对照组。
在研究结束时，测量了血清 FGF23、dp-uc-MGP 和 uc-OC 的水平。结果发现，与健康正常对照组相比，血液透析患者的 dp-uc-MGP、uc-OC 和 FGF23 血清水平显著升高（p<0.05）。4 个月后，与其他组相比，第 3 组 dp-uc-MGP 和 uc-OC 下降最为显著。然而，FGF23 没有变化。
维生素 K2 和天然维生素 D 对儿科血液透析患者的钙化调节剂有有益的影响。
clinicaltrial.gov（NCT04145492）。
